Who has been buying Engenbio stock?

1 distinct insiders have filed 5 disclosed insider purchases in Engenbio (354200), most recently on 2026-06-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Engenbio have?

Engenbio has 5 buy-side and 0 sell-side disclosures on record, covering ₩99M ($68K) in total reported value, spanning 2024-04-09 to 2026-06-25.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Engenbio 354200

Company

엔젠바이오Engenbio

Insiders

Buys

Total Value

₩99M ($68K)

Avg Return

-32.98%

Last Filing

2026-06-25

Engenbio (354200) has 5 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩99M ($68K) in reported transaction value. The earliest filing StockDrifts holds for Engenbio is dated 2024-04-09; the most recent is 2026-06-25. Across these filings the average return since disclosure is -32.98%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-14	SELL	장외매도	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	-785.6K	₩1,998	+0.0%	₩1.6B ($1.1M)
2026-08-04	BUY	기타	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	1.6M	₩1,747	+4.6%	₩2.7B ($1.9M)
2026-07-29	BUY	Market Buy	김민식 Minsik Kim	CEO	30.2K	₩1,545	+4.9%	₩72M ($50K)
2026-07-28	BUY	Market Buy	김민식 Minsik Kim	CEO	12.5K	₩1,745	-7.1%	₩28M ($20K)
2026-06-25	SELL	자본감소	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	-3.9M	-	-	-
2026-06-25	SELL	자본감소	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	-392.4K	₩2,150	+22.4%	₩844M ($586K)
2025-09-01	SELL	장외매도	홍창범 Hong Chang-beom	general manager	-6.0K	₩1,777	-9.2%	₩11M ($7K)
2025-09-01	SELL	장외매도	김광중 Gwangjoong Kim	Director of Research Institute	-108.0K	₩1,777	-9.2%	₩192M ($133K)
2025-08-01	SELL	장외매도	홍창범 Hong Chang-beom	general manager	-94.0K	₩1,756	-10.5%	₩165M ($115K)
2025-08-01	SELL	장외매도	최대출 maximum output	vice president	-80.0K	₩1,756	-10.5%	₩140M ($98K)
2025-06-28	BUY	신규보고	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	5.9M	-	-	-
2025-06-28	BUY	신규보고	에스에이치헬스케어투자1호조합 SH Healthcare Investment Association No. 1	-	5.9M	-	-	-
2024-12-20	BUY	유상신주취득	홍창범 Hong Chang-beom	general manager	31.7K	₩2,130	-8.9%	₩67M ($47K)
2024-12-20	BUY	주식매수선택권	최대출 maximum output	CEO	80.3K	₩2,130	-8.9%	₩171M ($119K)
2024-12-18	BUY	유상신주취득	윤세혁 Sehyuk Yoon	general manager	15.0K	₩2,295	-15.4%	₩34M ($24K)
2024-12-18	BUY	유상신주취득	최대출 maximum output	CEO	134.2K	₩2,295	-15.4%	₩308M ($214K)
2024-12-18	BUY	유상신주취득	김지연 Jiyeon Kim	general manager	2.0K	₩2,295	-15.4%	₩5M ($3K)
2024-12-18	BUY	유상신주취득	김광중 Gwangjoong Kim	Internal director	43.2K	₩2,295	-15.4%	₩99M ($69K)
2024-12-09	SELL	기타	윤세혁 Sehyuk Yoon	general manager	-11.1K	₩2,010	+3.4%	₩22M ($15K)
2024-12-09	SELL	기타	김지연 Jiyeon Kim	general manager	-1.7K	₩2,010	+3.4%	₩3M ($2K)
2024-12-09	SELL	기타	홍창범 Hong Chang-beom	general manager	-25.8K	₩2,010	+3.4%	₩52M ($36K)
2024-12-09	SELL	기타	김광중 Gwangjoong Kim	Internal director	-33.2K	₩2,010	+3.4%	₩67M ($46K)
2024-12-09	SELL	기타	최대출 maximum output	CEO	-110.7K	₩2,010	+3.4%	₩223M ($155K)
2024-11-20	SELL	장외매도	최대출 maximum output	CEO	-129.5K	₩2,695	+28.0%	₩349M ($242K)
2024-11-20	SELL	장외매도	김지연 Jiyeon Kim	general manager	-4.7K	₩2,695	+28.0%	₩13M ($9K)
2024-11-20	SELL	장외매도	홍창범 Hong Chang-beom	general manager	-78.0K	₩2,695	+28.0%	₩210M ($146K)
2024-11-20	SELL	장외매도	윤세혁 Sehyuk Yoon	general manager	-27.2K	₩2,695	+28.0%	₩73M ($51K)
2024-11-20	SELL	장외매도	김광중 Gwangjoong Kim	Internal director	-37.2K	₩2,695	+28.0%	₩100M ($70K)
2024-11-14	BUY	기타	윤세혁 Sehyuk Yoon	general manager	38.3K	₩2,395	-19.0%	₩92M ($64K)
2024-11-14	BUY	기타	홍창범 Hong Chang-beom	general manager	103.8K	₩2,395	-19.0%	₩249M ($173K)
2024-11-14	BUY	기타	김지연 Jiyeon Kim	general manager	6.4K	₩2,395	-19.0%	₩15M ($11K)
2024-11-14	BUY	기타	최대출 maximum output	CEO	240.2K	₩2,395	-19.0%	₩575M ($400K)
2024-11-14	BUY	기타	김광중 Gwangjoong Kim	Internal director	70.4K	₩2,395	-19.0%	₩169M ($117K)
2024-07-17	BUY	Market Buy	최대출 maximum output	CEO	1.1K	₩2,718	-28.6%	₩3M ($2K)
2024-07-16	BUY	Market Buy	최대출 maximum output	CEO	4.7K	₩2,709	-28.4%	₩13M ($9K)
2024-07-15	BUY	Market Buy	최대출 maximum output	CEO	5.8K	₩2,709	-28.4%	₩16M ($11K)
2024-07-12	BUY	Market Buy	최대출 maximum output	CEO	10.0K	₩2,695	-28.0%	₩27M ($19K)
2024-04-30	BUY	Market Buy	최대출 maximum output	CEO	10.0K	₩4,012	-51.6%	₩40M ($28K)
2024-04-15	SELL	장외매도	젠큐릭스 Gencurix	-	-640.0K	₩6,214	+68.8%	₩4.0B ($2.8M)
2024-04-09	BUY	장외매수	최대출 maximum output	CEO	10.0K	₩5,930	-67.3%	₩59M ($41K)
2024-04-09	SELL	장외매도	젠큐릭스 Gencurix	-	-220.0K	₩5,930	+67.3%	₩1.3B ($906K)
2024-04-09	BUY	장외매수	김광중 Gwangjoong Kim	Internal director	10.0K	₩5,930	-67.3%	₩59M ($41K)

Frequently asked questions

Who has been buying Engenbio stock?: 1 distinct insiders have filed 5 disclosed insider purchases in Engenbio (354200), most recently on 2026-06-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Engenbio have?: Engenbio has 5 buy-side and 0 sell-side disclosures on record, covering ₩99M ($68K) in total reported value, spanning 2024-04-09 to 2026-06-25.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.